E
Eric Y. Chen
Researcher at Fred Hutchinson Cancer Research Center
Publications - 4
Citations - 919
Eric Y. Chen is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: CTL* & Cytotoxic T cell. The author has an hindex of 2, co-authored 4 publications receiving 851 citations.
Papers
More filters
Journal ArticleDOI
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.
Brian G. Till,Brian G. Till,Michael C. Jensen,Jinjuan Wang,Eric Y. Chen,Brent L. Wood,Harvey A. Greisman,Xiaojun Qian,Scott E. James,Andrew Raubitschek,Stephen J. Forman,Ajay K. Gopal,Ajay K. Gopal,John M. Pagel,John M. Pagel,Catherine G. Lindgren,Philip D. Greenberg,Philip D. Greenberg,Stanley R. Riddell,Stanley R. Riddell,Oliver W. Press,Oliver W. Press +21 more
TL;DR: The results of a proof-of-concept clinical trial in which patients with relapsed or refractory indolent B-cell lymphoma or mantle cell lymphoma were treated with autologous T cells genetically modified by electroporation with a vector plasmid encoding a CD20-specific chimeric T- cell receptor and neomycin resistance gene show the safety, feasibility, and potential antitumor activity of adoptive T-cell therapy using this approach.
Journal ArticleDOI
Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains.
Jinjuan Wang,Michael C. Jensen,Yukang Lin,Xingwei Sui,Eric Y. Chen,Catherine G. Lindgren,Brian G. Till,Andrew Raubitschek,Stephen J. Forman,Xiaojun Qian,Scott E. James,Philip D. Greenberg,Stanley R. Riddell,Oliver W. Press +13 more
TL;DR: This study provides the preclinical basis for a clinical trial of adoptive T cell immunotherapy for patients with relapsed CD20+ mantle cell lymphoma and indolent lymphomas and verified the superiority of generating genetically modified polyclonal T cells expressing the second-generation cTCR rather than T cell clones.
Journal ArticleDOI
354. CD8 Immunomagnetic Selection and Interleukin-15 (IL-15) Facilitate the Isolation of Human CD8+ Cytotoxic T-Lymphocytes (CTL) Genetically Engineered To Express an Anti-CD20 Chimeric T-Cell Receptor (cTCR)
TL;DR: CD20-specific CTL are cytotoxic in vitro and in vivo and CD8 selection and IL-15 facilitate the isolation of these clones, anticipated to improve the yield of anti-CD20 clones for a planned phase I clinical trial treating patients with relapsed follicular non-Hodgkin's lymphoma.
CD20-specific T cells mantle cell lymphoma using genetically modified autologous Adoptive immunotherapy for indolent non-Hodgkin lymphoma and
Catherine G. Lindgren,Philip D. Greenberg,Stanley R. Riddell,Oliver W. Press,Xiaojun Qian,Scott E. James,Andrew Raubitschek,Stephen J. Forman,Ajay K. Gopal,Michael C. Jensen,Jinjuan Wang,Eric Y. Chen,Brent L. Wood,Harvey A. Greisman +13 more